StockWatch
·
HomeLiveWeekly

Inhibikase Therapeutics, Inc.

Ticker: 1750149

OverviewP/LShare Hold
values in millions

Revenue & Profit Trend

in millions
RevenueExpenditureNet Profit
-7.60-2.352.898.13Q3 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q1 FY2023Q1 FY2023Q2 FY2023Q3 FY2023

Margin Trend

percentage
OPM %NPM %
-102.00-100.67-99.33-98.00Q3 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q1 FY2023Q1 FY2023Q2 FY2023Q3 FY2023
PeriodQ3 FY2023Q2 FY2023Q1 FY2023Q1 FY2023Q3 FY2022Q2 FY2022Q1 FY2022Q3 FY2021
INCOME
Revenue0.08-33.3%0.12+100.0%0.06+0.0%0.06+500.0%0.01+0.0%0.01-80.0%0.05-84.8%0.33
Total Income0.08-33.3%0.12+100.0%0.06+0.0%0.06+500.0%0.01+0.0%0.01-80.0%0.05-84.8%0.33
EXPENSES
Expenditure4.85-23.3%6.32+32.2%4.78+0.0%4.78+5.8%4.52-2.8%4.65-0.9%4.69-2.3%4.80
Tax0.000.000.000.00——0.00—
PROFIT
Net Profit-4.60+20.4%-5.78-29.0%-4.48+0.0%-4.48+0.2%-4.49+3.2%-4.64+0.0%-4.64-3.8%-4.47
KEY METRICS
OPM %-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%
NPM %-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%-100.00%
EPS-0.86+22.5%-1.11-593.8%-0.16+83.7%-0.98-444.4%-0.18+0.0%-0.18——

Corporate Events

Board MeetingIKT
2026
26Jun

Board Meeting

Annual Meeting of Stockholders to elect directors, ratify au…

SEC Filing ↗